Leydig cell tumors of the testis: a case report

Ancuta Augustina Gheorghisan-Galateanu

Abstract

Background: Leydig cell tumors are the most common non-germ cell gonadal tumors with apparent increased incidence in the last few years. They are usually benign tumors. We report a case of Leydig cell tumor of testis in a patient presenting atypical features.

Case presentation: A 29-year-old Caucasian man, born with right cryptorchidism, corrected without medical treatment before the age of two years, was diagnosed with Leydig cell tumor. Two years after diagnosis was identified moderately elevated estradiol serum level, in the context of a significant overweight, hormonal changes which had maintained after unilateral orchiectomy and after the patient’s return to normal weight. Four years after unilateral orchiectomy, elevated value of estradiol persisted and subdiaphragmatic micro lymphadenopathy was observed.

Conclusions: Despite the favorable evolution of the patient four years after unilateral orchiectomy, long-term follow-up is necessary to exclude recurrence or metastasis to the testis. The endocrine profile and imaging investigations need to be repeated periodically. The changes in the hormonal assay and any new aspects on computed tomography scan can be used as a marker of tumor recurrence and require careful screening and the correct therapeutic decisions.

Keywords: Leydig cell tumor, Overweight, Gynecomastia, Estradiol, Subdiaphragmatic micro lymphadenopathy

Background

Approximately 5-6% of all testis tumors are non-germ cell tumors. Included in this group are sex cord/gonadal stromal tumors, most originating from Leydig or Sertoli cells, mixed tumors, and tumors of mesenchymal or hematopoietic origin [1].

Leydig cell tumors (LCTs) are uncommon neoplasms arising from gonadal stroma, accounting for 1-3% of all testicular tumors in adults and 4% in prepubertal children [2,3]. In the last few years the incidence of LCTs seemed to increase well above the literature predictions (14.7% of all testicular tumors removed). One possible explanation for this phenomenon is the increasing use of better ultrasound technology and the subsequent increased detection of small nodules that have not been found in historical series [4]. We communicate a case of Leydig cell tumor with atypical evolution marked by maintaining of moderately elevated estradiol serum level four years after unilateral orchiectomy.

Case presentation

A 29-year-old Caucasian man presented to the endocrinology department with a recent right testicular mass observed at self-examination. The patient was born with right cryptorchidism. The right testis moved down into the scrotum before the age of two years old, without medical treatment. His family history revealed a lung cancer at his paternal grandfather. On physical examination the right testis was 6.5 × 3.5 cm in size, with a palpable tumoral mass of approximately 1.93 × 1.30 cm in size. No other sign, including gynecomastia or swelling of superficial lymph nodes was observed. Scrotal ultrasonography revealed a non-homogenous hypoechoic tumoral mass in the right testis (Figure 1). Tumor markers such as alpha-fetoprotein (AFP) and β-human chorionic gonadotropin (β-hCG) were negative, and hormonal investigations were normal (Table 1). Surgery was indicated but the patient refused. He returned to the endocrinology department after two years with scrotal pain in the last month. One year before the patient has
successfully fathered a child. Over these two years the patient overgrowth 30 kilos (at initial examination weight 90 kilos/height 195 cm). On physical examination the testicular tumor mass has not changed in size and scrotal ultrasound had the same aspect, but gynecomastia was present. The tumor markers (AFP and β-hCG) were also negative and hormonal investigations were normal, except moderately elevated estradiol level (E2) and low normal level of testosterone (T) (Table 1). This time the patient accepted surgery. With a diagnosis of right testicular tumor, radical right high orchiectomy was performed and the specimen has been submitted for histopathological examination. The final diagnosis of benign Leydig cell tumor of testis was given (Figure 2). Immunohistochemical profile showed diffuse positive staining for Calretinin, Vimentin and CD99 and negative staining for Synaptophysin and Cytokeratin AE1/AE3. Hormonal investigations made after surgery showed still the persistence of a moderate increase of serum level of E2, while tumor markers AFP and β-hCG were still negative (Table 1). The postsurgical evolution was favorable. With diet and physical activity, the patient returned to normal weight one year after the unilateral orchiectomy. Without further treatment, the patient was evaluated yearly. The blood tests including tumor markers and hormonal investigations, along with scrotal ultrasound, abdominal and pelvis computed tomography (CT) scan were normal, except E2 serum level which was moderately increased each time (Table 1). The abdominal CT scan

| Table 1 Tumor markers and hormonal evaluation at baseline, after surgery, and in the follow-up |
|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| 2 y | Before Surgery | After Surgery | 1 y | After surgery | 2 y | After surgery | 3 y | After surgery | 4 y | After surgery | Normal range for age |
|------|----------------|---------------|------|---------------|------|---------------|------|---------------|------|---------------|---------------------|
| AFP, ng/ml | 2.26 | 1.80 | 2.88 | 2.16 | 3.46 | 2.68 | 3.20 | < 44 |
| β-hCG, mIU/ml | 0.10 | 0.06 | 0.09 | 0.08 | 0.20 | 0.16 | 0.13 | 0.5-2.67 |
| Total testosterone, ng/ml | 4.23 | 1.80 | 2.40 | 4.60 | 6.26 | 6.60 | 4.40 | 1.75-7.81 |
| Estradiol, pg/ml | 26.31 | 80.22 | 61.31 | 78.4 | 62.43 | 75.36 | 78.96 | < 47 |
| LH, mIU/ml | 5.34 | 1.76 | 2.40 | 4.58 | 5.32 | 3.67 | 4.84 | 1.24-8.62 |
| FSH, mIU/ml | 4.23 | 3.80 | 2.49 | 2.80 | 4.12 | 2.74 | 3.85 | 1.27-19.26 |
| 17-KS, mg/24 hours | 23.4 | 17.9 | 18.75 | 18.8 | 22.3 | 19.6 | 21.4 | 17-25 |
| 17-HOCS, mg/24 hours | 8.4 | 10.22 | 9.07 | 8.8 | 7.40 | 9.22 | 8.94 | 2.10 |
| Progesterone, ng/ml | - | - | 0.09 | - | - | - | - | 0.10-0.84 |
| TSH, μIU/ml | - | 3.14 | 2.9 | 2.5 | - | - | - | 0.5-4.5 |

Abbreviations: AFP alpha-fetoprotein, β-hCG β-human chorionic gonadotropin, FSH follicle-stimulating hormone, LH luteinizing hormone, 17-KS urinary 17-ketosteroids, 17-HOCS urinary 17-hydroxycorticosterone, TSH Thyroid-stimulating hormone.
performed, four years after surgery, showed subdiaphragmatic micro lymphadenopathy (5–10 mm).

**Discussion**

The etiology of LCTs is unknown and it seems to be heterogeneous. Furthermore, the molecular basis of LCTs is poorly understood. Some studies showed a possible role of genetic factors in the etiology of this tumor. Interestingly, genetic mutations identified to date in child and adult were different, and in some cases have been associated with other cancers [5].

Some authors have reported in Leydig tumors in adult a somatic activating mutation in the guanine nucleotide-binding protein α gene, which may result in tumor development, leading to overexpression on the inhibin alpha subunit and hyperactivity of the testosterone biosynthetic pathway [6]. Also, in adult, it has been reported inherited fumarate hydratase mutation which appear to cause tumor growth through activation of the hypoxia pathway [7]. Alterations in local stimuli, including müllerian-duct inhibitory factor, inhibin, growth factors, and temperature, may also create favorable conditions for tumorigenesis [8].

LCTs are usually unilateral. However, 3-10% of them have been estimated to be bilateral and 15% may extend beyond the testis at the time of presentation. Origin from testicular Leydig cells is demonstrable in most cases, but rarely they may originate from the epididymis [9]. Although these tumors arise at any age, they affects mostly men between 20–60 years old.

In our case the tumor was unilateral in right testis and the patient belongs to the age group with the highest incidence.

LCTs may be an incidental finding of a testicular mass on scrotal ultrasonography performed for other conditions [10]. Except for the testicular tumor mass present in all cases, other signs and symptoms may be present in different degrees (pain in the testis, enlargement of a testicle, heaviness in the scrotum, and gynecomastia). Azospermia and infertility are uncommon and, if exist they are reversible after removal of the tumor [11].

Ultrasound of scrotum is very useful to confirm the diagnosis of testicular tumor [12], but it cannot differentiate between a benign and a malignant tumor [13]. In our case scrotal ultrasonography has revealed a non-homogenous hypechogenic tumoral mass in the right testis.

In patients with LCTs the blood tests for tumor markers (AFP, β- hCG, and lactate dehydrogenase) are negative.

The most common hormones secreted by LCTs are testosterone and estrogens. In most cases, adults have non functional testicular masses.

In our case tumor markers were always negative. Hormonal profile was initially normal. Two years after the discovery of the tumor the occurrence of gynecomastia and moderately elevated E2 serum level associated with decreased T to lower normal serum value was observed. After unilateral orchietomy the blood tests were normal,
except E2 serum level which was moderately increased each time (Table 1).

The use of fine needle aspiration for diagnosis may be an alternative to more invasive biopsy procedures in the preoperative diagnosis of this rare testicular tumor [14].

CT scan of the abdomen and pelvis and chest radiography are indicated especially if malignancy is suspected. In our case, except the tumor in the right testis, CT scan was normal.

Orchiectomy is the initial treatment for LCTs, with or without removal of nearby lymph nodes (lymphadenectomy). Today, some authors suggest a more conservative therapy. Testis sparing surgery has proved to be a feasible and safe choice and could be regarded as first-line therapy in cases of benign, small tumors (under 25 mm), and young men [15-19].

Although orchiectomy is curative in approximately 90% of cases, the remaining patients can develop metastases refractory to chemotherapy and radiations. Radical orchiectomy remains in use if malignancy is suspected [20].

In our case, based on family and personal medical history, radical right orchiectomy was performed.

The pathological exam and immunohistochemistry are essential for the diagnosis and for the next steps in treatment. In our case, no histopathological feature suggestive of malignancy was seen and the final diagnosis of benign Leydig cell tumor of testis was given. The results of immunoreactive tests were consistent with the existing literature (Table 2) [21-28].

While benign, LCTs have malignant potential in about 10% of cases with metastatic forms, particular to the lymph nodes, especially the retroperitoneal and inguinal nodes (70%), liver (45%), lungs (40%), and bone (25%) [29]. The metastatic type occurs exclusively in adults and is more common in older patients with an average age of more than 40 years. The risk of malignancy in the undescended testis is 4 to 10 times higher than that in the general population but the most common type of testicular cancer occurring in undescended testes is seminoma [30].

Palazzo et al. have suggested that the majority of LCTs are diploid and the less common malignant tumors are typically aneuploid, and that deoxyribonucleic acid flow cytometric findings can be useful as a prognostic indicator in these tumors [31].

In our case all clinical, hormonal, immunocytochemical, and pathological findings have supported the diagnosis of benign LCT.

Initially, starting from negative tumor markers and normal hormonal profile, tumoral mass seemed to be a non functional Leydig cell tumor, the only detectable element has been testicular tumor mass. After two years the occurrence of gynecomastia and moderately elevated E2 serum level associated with decreased testosterone to lower normal serum value was observed which led to a new considerations of the case presented. Leydig cells can synthesize both androgens and estrogen, and this cells contain the aromatase enzyme necessary to convert irreversibly testosterone to estradiol [32]. There have been reported cases of Leydig cell tumor which demonstrated only an increase of serum E2 and suppression of serum testosterone as a consequence of increased aromatase activity in tumoral Leydig cells [33]. The direct inhibitory action of elevated E2 on the enzymes involved in steroidogenesis and the negative feedback action on luteinizing hormone secretion of the E2 possibly caused the suppression of serum testosterone [34]. Due to the significant increase in weight of the patient, in our case hormonal changes were rather considered a consequence of aromatization in adipose tissue of testosterone to estradiol and gynecomastia as a consequence of increased levels of estradiol and change of estrogen/androgen ratio. This assumption was confirmed by maintaining high levels of estradiol after unilateral orchiectomy, because it was demonstrated that after removing the tumor, in most cases, hormone levels return to normal, which in the case presented did not. Therefore has been indicated to the patient the weight loss in the hope that he will return to normal levels of estradiol and gynecomastia will disappear. Surprisingly, after the return

| Table 2 Immunohistochemical staining results of Leydig cell tumors |
|---------------------------------------------------------------|
| Marker               | Immunoreactivity |
|----------------------|------------------|
| **Benign Leydig cell tumors** |                 |
| Inhibin A           | +                |
| Calretinin*         | +                |
| Melan A (Mart-1)    | +                |
| Vimentin*           | +                |
| S-100               | +                |
| Synaptophysin*      | +/-              |
| Chromogranin        | +                |
| CD99*               | +                |
| P- /N-Cadherin      | +                |
| RLF/INSL3           | +                |
| StAR protein        | +                |
| SF-1                | +                |
| Cytokeratin*        | -                |
| PLAP                | -                |
| CD-30               | -                |
| Oct3/4              | -                |
| **Malignant Leydig cell tumors** |           |
| Ki67                | +                |
| p53                 | +                |
| Bcl2                | +                |

Abbreviations: RLF/INSL3 Relaxin-like factor/Insulin-like 3, StAR-protein Steroidogenic Acute Regulatory protein, SF-1 Steroidogenic factor 1, PLAP Placental Alkaline Phosphatase. *Immunohistochemical tests performed in our case.
to normal weight, estradiol levels continued to be slightly increased in the absence of any identifiable factors that could explain the maintenance of high levels of estradiol, such as red meat abuse consumption [35].

Statistics show that LCTs are rarely malignant and they correlate with increasing age of the patient, tumor size (over 5 cm) and increased tumor mitotic index. These data were missing in our case. In 2002 Maeda et al. reported on an adult patient with a larger testicular tumor in whom metastasis of Leydig cell tumor was suggested by elevated serum estradiol 9 years after the removal of the primary tumor [36].

We cannot yet draw a conclusion. For four years our patient remained free of disease, with no evidence of recurrence or metastasis, but persistent moderate high levels of estradiol and the result of the last abdominal CT scan (subdiaphragmatic micro lymphadenopathy) do not definitely exclude this possibility. It is known that changes in hormonal assay can be used as a marker of tumor recurrence in patients followed. Furthermore, the patient has a family history of cancer and at birth he had cryptorchidism. These data require careful monitoring and correct therapeutic decisions. Although estradiol levels are not suggestive for a malignant lesion, imaging investigations are of great interest, and need to be repeated periodically. Moreover, endocrine evaluation is useful for patients with a Leydig cell tumor in whom endocrinological abnormality is demonstrated. Many times was told that the next step in such cases is “wait and see”, which for our patient seems to be the most appropriate thing.

Conclusions
Leydig cell tumors are uncommon neoplasms arising from gonadal stroma. It is critical for physicians to remember and do not overlook the possibility of this rare tumor. The self-examination of testicles appears to be a very important step for the diagnosis of testicular tumors.

In Leydig cell tumors orchiectomy is the elected therapeutic decision. In the absence of any sign of malignancy, long-term follow-up is necessary to exclude recurrence or metastasis. Because we cannot always identify the reasons for persistent elevated E2 serum level after unilateral orchiectomy for Leydig cell tumors, the endocrine profile and imaging investigations need to be repeated periodically.

Consent
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Abbreviations
LCTs: Leydig cell tumors; AFP: alpha-fetoprotein; β-hCG: β-human chorionic gonadotropin; E2: Estradiol; T: Testosterone; CT: Computed tomography.

Competing interests
The author declares that he has no competing interests.

Authors’ contributions
AAGG: collection and assembly of data, microscopic imaging in final form for publication, manuscript writing, conception and final design. The author has read and approved this final manuscript.

Acknowledgements
The author would like to thank Dr. L. Pop for his contribution in providing immunocytochemistry data and pathologic diagnosis.

Received: 13 June 2014 Accepted: 16 September 2014
Published: 18 September 2014

References
1. Dilworth JP, Farrow GM, Oesterling JE: Non-germ cell tumors of testis. Urology 1991, 37:399–417.
2. Emerson RE, Ulbright TM: Morphological approach to tumours of the testis and paratestis. J Clin Pathol 2007, 60:866–880.
3. Cheville JC: Classification and pathology of testicular germ cell and sex cord-stromal tumors. Urol Clin North Am 1999, 26:595–609.
4. Leonhartsberger N, Ramoner R, Aigner F, Stoehr B, Pichler R, Zangerl F, Fritzer A, Steiner H: Increased incidence of Leydig cell tumours of the testis in the era of improved imaging techniques. BJU Int 2011, 108:1630–1637.
5. Giacaglia LR, Kohek MB da F, Carvalho FM, Fragoso MC, Mendonca B, Latronico AC: No evidence of somatic activating mutations on gonadotropin receptor genes in sex cord stromal tumors. Fertil Steril 2000, 74:992–995.
6. Libe R, Fratticci A, Lahoud N, Jornayvaz FR, Tessier F, Loulier E, Gubourdeneche J, Viellevand A, Zerbi B, Bertherat J: A rare cause of hypertestosteronemia in a 68-year-old patient: a Leydig cell tumor due to a somatic GNAS (guanine nucleotide-binding protein, alpha-stimulating activity polypeptide 1)-activating mutation. J Androl 2012, 33:578–584.
7. Carvajal-Carmona LG, Alam NA, Pollard PJ, Jones AM, Barclay E, Wortham N, Pignatelli M, Freeman A, Pomplun S, Ellis I, Poulson R, El-Bahrawy MA, Berney DM, Tomlinson JP: Adult Leydig cell tumours of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab 2006, 91:3071–3075.
8. Lejeune H, Habert R, Saez JM: Origin, proliferation and differentiation of Leydig cells. J Mol Endocrinol 1998, 20:1–25.
9. Huang Y, Song J, Xu M, Zan Q: Primary Leydig cell tumour of epididymis: a rare case report with review of literature. Andrologia 2013, 45:430–433.
10. Buzulier C, Marcelli F, Ghonime T, Lemarine L, Puech L, Loray X, Rigo J: Management of testicular lesions in a population of infertile patients. Prog Urol 2012, 22:45–52.
11. Markou A, Vale J, Vadgama B, Walker M, Franks S: Testicular Leydig cell tumor presenting as primary infertility. Hormones (Athens) 2002, 1:251–254.
12. Negri L, Benaglia R, Fiamengo B, Pizzocaro A, Albani E, Levi Setti PE: Primary Leydig cell tumor: enucleation as a therapeutic choice in a case with atypical symptoms. Arch Esp Urol 2012, 65:897–899.
20. Bertram KA, Bratloff B, Hodges GF, Davidson H: Treatment of malignant Leydig cell tumor. Cancer 1991, 68:2324–2329.
21. Iczkowski KA, Bostwick DG, Roche PC, Cheville JC: Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol 1998, 11:774–779.
22. Bussam KJ, Iversen K, Coplan KA, Old LJ, Stockert E, Chen YT, McGregor D, Jungbluth A: Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical and other steroid tumors. Am J Surg Pathol 1998, 22:57–63.
23. Bremmer F, Schweyer S, Martin-Ortega M, Hemmerlein B, Strauss A, Radzun HJ, Behnes CL: Switch of cadherin expression as a diagnostic tool for Leydig cell tumors. APMIS 2013, 121:976–981.
24. McCluggage WG, Shank J, Whiteside C, Maxwell P, Banejee SS, Biggart JD: Immunohistochemical study of testicular sex cord-stromal tumors, including staining with anti-inhibin antibody. Am J Surg Pathol 1998, 22:615–619.
25. Hekimgil M, Altay B, Soydan S, Ozyurt C, Killi R: Leydig cell tumor of the testis: comparison of histopathological and immunohistochemical features of three azoospermic cases and one malignant case. Pathol Int 2001, 51:792–796.
26. Iczkowski KA, Butler SL: New immunohistochemical markers in testicular tumors. Anal Quant Cytol Histol 2006, 28:181–187.
27. Dong L, Wang H, Su Z, Niu S, Wang L, Chen G: Steroidogenic acute regulatory protein is a useful marker for Leydig cells and sex-cord stromal tumors. Appl Immunohistochem Mol Morphol 2011, 19:226–232.
28. Sangoi AR, McKenzie JK, Brooks JD, Higgins JP: Evaluation of SF-1 expression in testicular germ cell tumors: a tissue microarray study of 127 cases. Appl Immunohistochem Mol Morphol 2013, 21:318–321.
29. Farkas LM, Szekely JG, Pusztai C, Baki M: High frequency of metastatic Leydig cell testicular tumors. Oncology 2000, 59:118–121.
30. Palazzo JP, Petersen RO, Young RH, Scully RE: Deoxyribonucleic acid flow cytometry of testicular Leydig cell tumors. J Urol 1994, 152:415–417.
31. Carreau S, Bois C, Zanatta L, Silva FR, Bouraima-Lelong H, Delalande C: Estrogen signaling in testicular cells. Life Sci 2011, 89:584–587.
32. Masumori N, Kumamoto Y, Itoh N, Tsukamoto T, Miyao N, Koroku M, Hirose T, Takahashi S: Leydig cell tumor: a case report with reference to its endocrinological features. Eur Urol 1993, 24:302–304.
33. Rieu M, Kuhn JM, Mandard JC, Bottet P, Lemonnier D, Belka S, Mahoudeau J: Luteinizing hormone regulation by sex steroids in men with germinal and Leydig cell tumours. Clin Endocrinol (Oxf) 1993, 38:487–493.
34. Tavolini JM, Riosato M, Milani C, Dal Moro F: Estradiol plasma levels elevation during follow-up for testicular Leydig-cell tumor is not an unfailling sign of recurrence. Arch Ital Urol Androl 2007, 79:141–142.
35. Maeda T, Itoh N, Kobayashi K, Takahashi A, Masumori N, Tsukamoto T: Elevated serum estradiol suggesting recurrence of Leydig cell tumor nine years after radical orchidectomy. Int J Urol 2002, 9:659–661.

doi:10.1186/1756-0500-7-656
Cite this article as: Gheorghisan-Galateanu: Leydig cell tumors of the testis: a case report. BMC Research Notes 2014 7:656.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit